How big is Nuwellis, Inc.?

As of Jun 18, Nuwellis, Inc. has a market capitalization of 1.30 million, with net sales of 8.78 million and a net profit of -9.84 million over the last four quarters. Shareholder's funds are reported at 6.53 million, and total assets amount to 9.86 million.

As of Jun 18, Nuwellis, Inc. has a market capitalization of 1.30 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 8.78 million, while the sum of net profit for the same period is -9.84 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 6.53 million, and the total assets amount to 9.86 million.

What does Nuwellis, Inc. do?

Nuwellis, Inc. is a micro-cap medical device company specializing in ultrafiltration therapy. As of March 2025, it reported net sales of $2 million and a net loss of $3 million, with a market cap of $1.30 million.

Overview:<BR>Nuwellis, Inc. is a medical device company focused on developing, manufacturing, and commercializing medical devices for ultrafiltration therapy, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 1.30 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.65<BR>- Return on Equity: -415.47%<BR>- Price to Book: 0.36<BR><BR>Contact Details:<BR>- Address: 12988 Valley View Rd, EDEN PRAIRIE MN: 55344-3657<BR>- Tel: 1 952 3454200<BR>- Website: https://www.chf-solutions.com/

Should I buy, sell or hold Nuwellis, Inc.?

Who are in the management team of Nuwellis, Inc.?

As of March 2022, the management team of Nuwellis, Inc. includes Chairman John Erb, Lead Independent Director Warren Watson, and Independent Directors Steven Brandt, Maria Costanzo, Jon Salveson, and Gregory Waller.

As of March 2022, the management team of Nuwellis, Inc. includes the following individuals:<BR><BR>- Mr. John Erb, Chairman of the Board<BR>- Mr. Warren Watson, Lead Independent Director<BR>- Mr. Steven Brandt, Independent Director<BR>- Dr. Maria Costanzo, Independent Director<BR>- Mr. Jon Salveson, Independent Director<BR>- Mr. Gregory Waller, Independent Director

Is Nuwellis, Inc. overvalued or undervalued?

As of March 23, 2017, Nuwellis, Inc. is considered overvalued and carries a "risky" valuation grade due to its negative P/E ratio and significantly low EV to EBITDA and EV to EBIT ratios compared to its peers.

As of 23 March 2017, Nuwellis, Inc. has moved from a valuation grade of "does not qualify" to "risky." The company is currently considered overvalued given its financial metrics and peer comparisons. The price-to-book value stands at 0.49, while the EV to EBITDA and EV to EBIT ratios are both at 0.06, indicating significant underperformance relative to typical valuation standards.<BR><BR>In comparison to its peers, Nuwellis, Inc. shows a negative P/E ratio of -0.0872, while Nexalin Technology, Inc. and SINTX Technologies, Inc. have P/E ratios of -2.2805 and -1.0287, respectively. This suggests that Nuwellis is not only underperforming but also carries a higher risk profile compared to its peers. Given these factors, the company is deemed overvalued in the current market context.

Is Nuwellis, Inc. technically bullish or bearish?

As of August 1, 2025, Nuwellis, Inc. shows a mildly bullish technical trend despite mixed indicators, underperforming the S&P 500 with a year-to-date return of -91.89%.

As of 1 August 2025, the technical trend for Nuwellis, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bullish, while the monthly MACD also indicates a mildly bullish stance. However, the weekly RSI is bearish, contrasting with the monthly RSI which is bullish. The Bollinger Bands and Dow Theory show bearish signals on both weekly and monthly time frames. Moving averages are bearish on a daily basis, and the KST is bearish weekly but mildly bullish monthly. Overall, the technical stance is mildly bullish but mixed, with key indicators showing weakness in the short term.<BR><BR>In terms of performance, Nuwellis has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -91.89% compared to the S&P 500's 12.22%.